Get the Daily Brief
Latest Biotech News
Breakthroughs in Neuroscience and Rare Disease
New research points to innovative approaches in neuroscience and rare disorders. AAV-OTOF gene therapy shows promise restoring hearing in children and adults. Studies reveal microglia replacement...
Merck bolsters respiratory pipeline with $10B Verona Pharma acquisition
Merck & Co. struck a $10 billion deal to acquire Verona Pharma, expanding its portfolio with the COPD drug Ohtuvayre. The medication, an inhaled dual inhibitor of PDE3 and PDE4, combines...
FDA unveils drug rejection letters signaling shift toward transparency
In a historic policy shift, the U.S. Food and Drug Administration released over 200 complete response letters (CRLs) outlining reasons behind drug and biologic rejection decisions between 2020 and...
Capricor’s Duchenne cell therapy rejected by FDA amid trial data concerns
Capricor Therapeutics received a Complete Response Letter from the FDA rejecting its biologics license application for deramiocel, an allogeneic cell therapy aimed at treating cardiomyopathy in...
AI accelerates protein dynamics modeling to boost drug discovery
Researchers from Microsoft Research AI unveiled BioEmu, a generative deep learning model capable of rapidly predicting protein conformational ensembles with high accuracy. Published in Science,...
AbbVie inks $700M deal for trispecific antibody targeting multiple myeloma
AbbVie secured exclusive rights to ISB-2001, a trispecific antibody developed by IGI Therapeutics that simultaneously engages BCMA, CD38, and CD3 to treat relapsed/refractory multiple myeloma. The...
Soleno’s rare disease drug Vykat XR beats sales expectations
Soleno Therapeutics reported early sales figures for Vykat XR, the first approved treatment for hyperphagia in Prader-Willi syndrome. The medicine’s net revenue for Q2 2025 is forecast between $31...
GREmLN AI model maps gene regulatory networks to decode cell behavior
Scientists from Columbia University and the Chan Zuckerberg Initiative developed GREmLN, a graph-based artificial intelligence model that better captures complex gene regulatory interactions than...
Juniper Genomics raises C$4.6M to expand IVF genomics testing
Juniper Genomics secured $3.5 million USD (approximately C$4.6 million) in seed funding to commercialize its genomics testing platform tailored for in vitro fertilization (IVF). The startup aims...
Biomanufacturing faces talent shortage risk by 2028, experts warn
Industry experts highlight a looming 'talent singularity' in biomanufacturing by 2028, driven by a shortage of skilled workers aligned with evolving technological demands. Jason Beckwith of...
Merck’s $10B Bet on Verona Expands COPD Pipeline
Merck & Co. has completed a $10 billion acquisition of Verona Pharma, adding the fast-growing COPD drug Ohtuvayre to its cardio-pulmonary portfolio. This inhaled dual inhibitor of PDE3 and PDE4...
FDA Unveils Drug Rejection Letters in Transparency Shift
The FDA has published over 200 complete response letters (CRLs), revealing reasons for drug application rejections between 2020 and 2024. These letters, for products later approved, provide...
AbbVie Pays $700M for IGI’s Trispecific Multiple Myeloma Antibody
AbbVie has secured global rights to IGI Therapeutics’ early-stage trispecific antibody, ISB-2001, targeting BCMA, CD38, and CD3 for multiple myeloma treatment. The $700 million upfront deal could...
Capricor’s Duchenne Muscular Dystrophy Cell Therapy Faces FDA Setback
Capricor Therapeutics has received a complete response letter (CRL) from the FDA rejecting its Biologics License Application (BLA) for deramiocel, an off-the-shelf cell therapy aimed at treating...
AI Models Revolutionize Cell Biology and Drug Discovery
Researchers from Columbia University and the Chan Zuckerberg Initiative have developed GREmLN, an AI-based virtual cell model that captures complex gene regulatory networks. Utilizing graph-based...
Soleno’s Rare Disease Drug Surges Past Expectations in Q2
Soleno Therapeutics’ first-quarter sales of Vykat XR, a treatment for the insatiable hunger in Prader-Willi syndrome, exceeded market forecasts with $31–33 million in net revenues. The launch...
Nuclidium and Actithera Lead New Wave in Radiopharmaceuticals Funding
The European radiopharma sector gains momentum as Nuclidium AG closed a CHF 79 million ($99 million) Series B funding round, advancing clinical development of copper isotope-based diagnostics and...
Advances in Antibody and Protein Engineering Platforms
Emerging technologies are shaping antibody and protein engineering: Cellecta introduced DriverMap scAIR kits enabling detailed T and B cell receptor sequencing at single-cell resolution without...
Jazz Pharmaceuticals Names Renée Galá as New CEO
Jazz Pharmaceuticals announced that its current President and Chief Operating Officer, Renée Galá, will succeed CEO and co-founder Bruce Cozadd, effective August 11. This leadership change follows...
Merck Acquires Verona Pharma in $10 Billion Deal for COPD Pipeline
Merck & Co. announced the acquisition of Verona Pharma for $10 billion, aiming to enhance its portfolio in cardio-pulmonary disease treatments with the inclusion of Verona's COPD drug, Ohtuvayre....